CYP2D6 and breast carcinoma: Our results extend the findings from an earlier study of 28 stage II and III breast cancer patients with recurrence and their matched controls at a single United States oncology center, which also reported no substantial modification of tamoxifen effectiveness by concomitant use of SSRI inhibitors of CYP2D6 (Lehmann et al, 2004).